Author: Takaesu, Yoshikazu ; Ie, Kenya ; Inada, Yasushi ; Shimizu, Eiji ; Hori, Hikaru ; Inada, Ken ; Yoshida, Eriko ; Aoki, Yumi ; Yamada, Hisashi ; Tsuboi, Takashi ; Watanabe, Koichiro ; Takeshima, Masahiro ; Sakurai, Hitoshi ; Mishima, Kazuo ; Kise, Morito

Abstract:

Aim:

Clinicians face difficulties in making treatment decisions for unspecified anxiety disorder due to the absence of any treatment guidelines. The objective of this study was to investigate how familiar and how often primary care physicians use pharmacological and nonpharmacological approaches to manage the disorder.

Methods:

A survey was conducted among 117 primary care physicians in Japan who were asked to assess the familiarity of using each treatment option for unspecified anxiety disorder on a binary response scale (0 = “unfamiliar,” 1 = “familiar”) and the frequency on a nine‐point Likert scale (1 = “never used,” 9 = “frequently used”).

Results:

While several benzodiazepine anxiolytics were familiar to primary care physicians, the frequencies of prescribing them, including alprazolam (4.6 ± 2.6), ethyl loflazepate (3.6 ± 2.4), and clotiazepam (3.5 ± 2.3), were low. In contrast, certain nonpharmacological options, including lifestyle changes (5.4 ± 2.3), coping strategies (5.1 ± 2.7), and psychoeducation for anxiety (5.1 ± 2.7), were more commonly utilized, but to a modest extent. When a benzodiazepine anxiolytic drug failed to be effective, primary care physicians selected the following management strategies to a relatively high degree: differential diagnosis (6.4 ± 2.4), referral to a specialist hospital (5.9 ± 2.5), lifestyle changes (5.2 ± 2.5), and switching to selective serotonin reuptake inhibitor (5.1 ± 2.4).

Conclusion:

Primary care physicians exercise caution when prescribing benzodiazepine anxiolytics for unspecified anxiety disorder. Nonpharmacological interventions and switching to SSRI are modestly employed as primary treatment options and alternatives to benzodiazepine anxiolytics. To ensure the safe and effective treatment of unspecified anxiety disorder in primary care, more information should be provided from field experts.

01 Jul 2022·Journal of clinical psychopharmacologyQ4 · MEDICINE

Transfer of Ethyl Loflazepate Into Cord Blood, Breast Milk, and Infant's Serum

Q4 · MEDICINE

Article

Author: Wada, Yuka Sano ; Saito, Jumpei ; Kawasaki, Hiroyo ; Tachibana, Yoshiyuki ; Yakuwa, Naho ; Yamatani, Akimasa ; Murashima, Atsuko ; Suzuki, Tomo ; Sago, Haruhiko

01 Aug 2021·Clinical case reports

Psychogenic fever due to worry about COVID‐19: A case report

Author: Imataki, Osamu ; Uemura, Makiko

Abstract:

Psychogenic fever is stress‐related hyperthermia that is recognized as a psychosomatic condition. We treated a 46‐year‐old Japanese man who was worrying about the coronavirus infection (COVID‐19) and had a fever with a maximum temperature of 38.1℃. The patient was tested twice for SRAS‐CoV‐2 using polymerase chain reaction (PCR), but both tests were negative. All tests were negative for organic diseases, including infections, allergy/collagen diseases, endocrine disorders, malignancies, and drugs‐induced conditions. The more he doubted the COVID‐19 in him, the more he complained of the already known various symptoms, such as smelling disorder. The patient believed firmly that he had COVID‐19 because PCR can be false negative. Finally, the patient was treated with the anxiolytic, loflazepate, at 4 mg/day. This treatment was highly effective. The patient's serum IL‐6 was 1.1 pg/ml (≤4.0). The patient was diagnosed with psychogenic fever due to irrational worry over coronavirus. Such typical cases should be treated with an anxiolytic.

100 Deals associated with Ethyl Loflazepate

External Link

KEGG	Wiki	ATC	Drug Bank
D01293	Ethyl Loflazepate	N05BA18	DB01545

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neurotic Disorders	JP	Meiji Seika Pharma Co., Ltd.	20 Sep 1988
Psychotic Disorders	JP	Meiji Seika Pharma Co., Ltd.	20 Sep 1988

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis